REGN up +2.74% percent right now. $REGN High is at 397.73 and the Low 387.19 with current volume of 431,443.
Recent News posted below.
REGN Regeneron Pharmaceuticals Recent Headline News
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 2 hrs 6 mins ago
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 390.01 (+2.74), YHOO: 48.38 (-1.03), AMZN: 309.34 (+4.23), BIIB: 327.06 (-0.81), VRTX: 117.51 (+0.57), FEYE: 32.07 (-0.32), LNKD: 227.72 (-1.53), EBAY: 54.10 (+0.21), GILD: 108.45 (+1.43), AMGN: 163.27 (+0.18), ABBV: 63.97 (+0.18), REGN: 396.27 (+10.30), CELG: 108.13 (+0.12)
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN)
at The Street - 2 hrs 25 mins ago
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
REGN: 396.27 (+10.30)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.64 (+0.83), AZN: 74.12 (+0.91), AMGN: 163.27 (+0.18), TEVA: 58.42 (+0.38), THRX: 12.99 (-0.45), GSK: 45.76 (+0.60), SNY: 46.80 (+0.61), REGN: 396.27 (+10.30), NVS: 92.48 (-0.15)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.41 (+0.11), SNY: 46.80 (+0.61), REGN: 396.19 (+10.22)
After Yesterday's Rally of 2.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 4:06PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $376.54 to a high of $386.86. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $381.00 on volume of 539,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 396.19 (+10.22)
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
REGN: 396.19 (+10.22)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.26 (+0.03), SNY: 46.80 (+0.61), GNW: 8.39 (+0.27), REGN: 396.02 (+10.05)
Regeneron updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:09AM CST
REGN: 396.02 (+10.05)
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis
DoctoRx - at Seeking Alpha - Thu Nov 06, 7:32AM CST
AMGN: 163.27 (+0.18), SNY: 46.80 (+0.61), REGN: 396.02 (+10.05)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 100.38 (+1.20), AMGN: 163.27 (+0.18), SNY: 46.80 (+0.61), REGN: 396.02 (+10.05)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 327.06 (-0.81), MNST: 107.43 (-0.33), ATI: 32.02 (+0.19), MON: 117.93 (+1.04), GMCR: 154.28 (-1.09), VMC: 65.45 (+0.03), EMR: 64.73 (-0.38), WDC: 97.40 (-0.24), VRSN: 60.34 (-0.13), URBN: 30.95 (+0.35), FSLR: 51.01 (-0.95), DE: 88.65 (+0.11), EXPE: 86.24 (+0.24), FLR: 65.68 (-0.28), FLS: 66.95 (-0.83), X: 35.39 (-1.31), ROK: 112.59 (-0.16), REGN: 396.02 (+10.05), MA: 84.41 (-0.44)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 117.51 (+0.57), GERN: 2.37 (+0.07), AMGN: 163.27 (+0.18), ABBV: 63.97 (+0.18), AEGR: 21.43 (-0.14), SNY: 46.80 (+0.61), REGN: 396.02 (+10.05)
Regeneron Pharmaceuticals Inc. Earnings: Eylea's Roller-Coaster Ride
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 04, 6:27PM CST
Regeneron Pharmaceuticals was down 6% today after releasing third-quarter earnings. While U.S. sales of its flagship drug Eylea rose 23% year over year in the third quarter and sales by its partner Bayer HealthCare outside the U.S. more than...
SNY: 46.80 (+0.61), REGN: 396.06 (+10.09)
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 5.79% Sell Off
Comtex SmarTrend(R) - Tue Nov 04, 3:51PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $368.45 to a high of $384.43. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $386.27 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 396.06 (+10.09)
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:30PM CST
Regeneron Pharmaceuticals' (REGN) third-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.23 per share surpassed the Zacks Consensus Estimate.
AMAG: 34.84 (-0.07), SNY: 46.80 (+0.61), REGN: 396.06 (+10.09)
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 3:16PM CST
The following Regeneron Pharmaceuticals (REGN) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
REGN: 396.10 (+10.13)
Regeneron Pharmaceuticals' (REGN) CEO Leonard Schleifer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 12:50PM CST
REGN: 396.00 (+10.03)
Regeneron falls after paring Eylea sales outlook
AP - Tue Nov 04, 11:52AM CST
NEW YORK (AP) — Shares of Regeneron Pharmaceuticals Inc. declined Tuesday after the company tightened its forecast for sales of Eylea, an eye drug that brings in almost all of its revenue.
REGN: 396.00 (+10.03)
Regeneron Pharmaceuticals (REGN) Stock Declines on Lower Eylea Revenue Guidance
at The Street - Tue Nov 04, 10:10AM CST
Regeneron Pharmaceuticals (REGN) shares are falling following the release of its third quarter earnings report.
REGN: 396.00 (+10.03)
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter
at Investor's Business Daily - Tue Nov 04, 9:51AM CST
Big-cap biotech Regeneron Pharmaceuticals (REGN) missed Wall Street's Q3 estimates and cut the top end off the guidance range for its best-selling drug, sending the stock down 5% in early trading on the stock market today . Regeneron's earnings,...
REGN: 396.00 (+10.03)
Recent News posted below.
REGN Regeneron Pharmaceuticals Recent Headline News
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 2 hrs 6 mins ago
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 390.01 (+2.74), YHOO: 48.38 (-1.03), AMZN: 309.34 (+4.23), BIIB: 327.06 (-0.81), VRTX: 117.51 (+0.57), FEYE: 32.07 (-0.32), LNKD: 227.72 (-1.53), EBAY: 54.10 (+0.21), GILD: 108.45 (+1.43), AMGN: 163.27 (+0.18), ABBV: 63.97 (+0.18), REGN: 396.27 (+10.30), CELG: 108.13 (+0.12)
Today's Momo Momentum Stock To Watch: Regeneron Pharmaceuticals (REGN)
at The Street - 2 hrs 25 mins ago
Trade-Ideas LLC identified Regeneron Pharmaceuticals (REGN) as a momo momentum candidate
REGN: 396.27 (+10.30)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.64 (+0.83), AZN: 74.12 (+0.91), AMGN: 163.27 (+0.18), TEVA: 58.42 (+0.38), THRX: 12.99 (-0.45), GSK: 45.76 (+0.60), SNY: 46.80 (+0.61), REGN: 396.27 (+10.30), NVS: 92.48 (-0.15)
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
PR Newswire - Tue Nov 11, 12:00AM CST
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
SAN: 8.41 (+0.11), SNY: 46.80 (+0.61), REGN: 396.19 (+10.22)
After Yesterday's Rally of 2.15% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Nov 10, 4:06PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $376.54 to a high of $386.86. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $381.00 on volume of 539,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 396.19 (+10.22)
Global Diabetic Retinopathy Therapeutics Pipeline Report H2 2014 - Analysis of 28 Companies & 44 Drug Profiles
M2 - Mon Nov 10, 10:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc9dhb/diabetic) has announced the addition of the "Diabetic Retinopathy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Kowa Company, Ltd. - Antisense Therapeutics Limited - BioDiem Ltd - Regeneron Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Paloma Pharmaceuticals, Inc. - Acucela Inc. - Gene Signal International SA - Promedior, Inc. - Inotek Pharmaceuticals Corporation - Angstrom Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Dimerix Bioscience Pty Ltd - Resolvyx Pharmaceuticals, Inc - Charlesson LLC. - MacuCLEAR, Inc. - Stelic Institute & Co. - EyeCyte, Inc. - Vascular Pharmaceuticals, Inc. - PanOptica, Inc. - EyeGene, Inc. - Targazyme, Inc. - Aprogen, Inc. - MingSight Pharmaceuticals - Bionure Farma, S.L. - Islet Sciences, Inc. - Foresee Pharmaceuticals, LLC - Biomar Microbial Technologies Drug Profiles - aflibercept (recombinant) - ripasudil - AKB-9778 - ATL-1103 - DG-3173 - emixustat hydrochloride - aganirsen - GLY-230 - EG-Mirotin - Small Molecules to Inhibit PARP for Oncology, Ophthalmology and Metabolic Disorders - DT-23552 - RX-20001 - A-6 - P-529 - BDM-E - RTU-007 - Mesenchymal Stem Cells - PRM-167 - A-717 - MS-553 - PAN-90806 - MC-4001 - AP-202 - FP-002 - Recombinant Protein for Cancer and Diabetic Retinopathy - Cyndacel-M - VPI-2690-B - Small Molecule for Diabetic Neuropathy and Retinopathy - TZ-101 - V-1932 For more information visit http://www.researchandmarkets.com/research/sc9dhb/diabetic
REGN: 396.19 (+10.22)
3 Crashing Stocks: Is 1 a Buy?
Motley Fool Staff - Motley Fool - Sun Nov 09, 10:45AM CST
Even though the overall stock market is very close to its record highs, many stocks have not fared so well. In fact, some stocks have gotten crushed recently. We asked three of our analysts to give their opinions on stocks that have been beaten...
VVUS: 3.26 (+0.03), SNY: 46.80 (+0.61), GNW: 8.39 (+0.27), REGN: 396.02 (+10.05)
Regeneron updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:09AM CST
REGN: 396.02 (+10.05)
Regeneron Plunges In What Barron's Calls A Significant Disappointment: My Analysis
DoctoRx - at Seeking Alpha - Thu Nov 06, 7:32AM CST
AMGN: 163.27 (+0.18), SNY: 46.80 (+0.61), REGN: 396.02 (+10.05)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 100.38 (+1.20), AMGN: 163.27 (+0.18), SNY: 46.80 (+0.61), REGN: 396.02 (+10.05)
20 Stocks That Could Beat the Market in November: Priceline, U.S. Steel Lead Way
at The Street - Wed Nov 05, 10:24AM CST
Which stocks have historically done the best in November, typically one of the best months to invest?
BIIB: 327.06 (-0.81), MNST: 107.43 (-0.33), ATI: 32.02 (+0.19), MON: 117.93 (+1.04), GMCR: 154.28 (-1.09), VMC: 65.45 (+0.03), EMR: 64.73 (-0.38), WDC: 97.40 (-0.24), VRSN: 60.34 (-0.13), URBN: 30.95 (+0.35), FSLR: 51.01 (-0.95), DE: 88.65 (+0.11), EXPE: 86.24 (+0.24), FLR: 65.68 (-0.28), FLS: 66.95 (-0.83), X: 35.39 (-1.31), ROK: 112.59 (-0.16), REGN: 396.02 (+10.05), MA: 84.41 (-0.44)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 117.51 (+0.57), GERN: 2.37 (+0.07), AMGN: 163.27 (+0.18), ABBV: 63.97 (+0.18), AEGR: 21.43 (-0.14), SNY: 46.80 (+0.61), REGN: 396.02 (+10.05)
Regeneron Pharmaceuticals Inc. Earnings: Eylea's Roller-Coaster Ride
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 04, 6:27PM CST
Regeneron Pharmaceuticals was down 6% today after releasing third-quarter earnings. While U.S. sales of its flagship drug Eylea rose 23% year over year in the third quarter and sales by its partner Bayer HealthCare outside the U.S. more than...
SNY: 46.80 (+0.61), REGN: 396.06 (+10.09)
Look for Shares of Regeneron Pharmaceuticals to Potentially Rebound after Yesterday's 5.79% Sell Off
Comtex SmarTrend(R) - Tue Nov 04, 3:51PM CST
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $368.45 to a high of $384.43. Yesterday, the shares fell 5.8%, which took the trading range below the 3-day low of $386.27 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 396.06 (+10.09)
Regeneron Q3 Earnings Up Y/Y, Narrows Eylea Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:30PM CST
Regeneron Pharmaceuticals' (REGN) third-quarter 2014 adjusted earnings (including stock-based compensation expense) of $2.23 per share surpassed the Zacks Consensus Estimate.
AMAG: 34.84 (-0.07), SNY: 46.80 (+0.61), REGN: 396.06 (+10.09)
Regeneron Pharmaceuticals (REGN) Earnings Report: Q3 2014 Conference Call Transcript
at The Street - Tue Nov 04, 3:16PM CST
The following Regeneron Pharmaceuticals (REGN) conference call took place on November 4, 2014, 08:30 AM ET. This is a transcript of that earnings call:
REGN: 396.10 (+10.13)
Regeneron Pharmaceuticals' (REGN) CEO Leonard Schleifer on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 12:50PM CST
REGN: 396.00 (+10.03)
Regeneron falls after paring Eylea sales outlook
AP - Tue Nov 04, 11:52AM CST
NEW YORK (AP) — Shares of Regeneron Pharmaceuticals Inc. declined Tuesday after the company tightened its forecast for sales of Eylea, an eye drug that brings in almost all of its revenue.
REGN: 396.00 (+10.03)
Regeneron Pharmaceuticals (REGN) Stock Declines on Lower Eylea Revenue Guidance
at The Street - Tue Nov 04, 10:10AM CST
Regeneron Pharmaceuticals (REGN) shares are falling following the release of its third quarter earnings report.
REGN: 396.00 (+10.03)
Regeneron Q3 Earnings Miss As U.S. Eylea Sales Falter
at Investor's Business Daily - Tue Nov 04, 9:51AM CST
Big-cap biotech Regeneron Pharmaceuticals (REGN) missed Wall Street's Q3 estimates and cut the top end off the guidance range for its best-selling drug, sending the stock down 5% in early trading on the stock market today . Regeneron's earnings,...
REGN: 396.00 (+10.03)
